Search

News Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics

Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying metabolic profiles. A recently conducted meta-analysis by Italian authors investigated the impact of second-generation antipsychotics on weight gain, BMI, lipid spectrum, and glycemia.

Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Acquired Hemophilia A Newly Diagnosed in an Elderly Patient −⁠ A Case Report

At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.

Source: Acquired Hemophilia 28. 3. 2022

News Trifluridine/tipiracil in Real Clinical Practice –⁠ Current Data from Spain

Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free survival (PFS). At this year's virtual World Congress on Gastrointestinal Cancer of the European Society for Clinical Oncology (ESMO), held from June 30, a Spanish study on the efficacy of trifluridine/tipiracil in real-world clinical practice was presented.

Source: Treatment of Gastrointestinal Carcinomas 9. 9. 2021

News How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio -⁠ and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been shown by the prospective randomized EMPA-REG OUTCOME study and the real-world EMPRISE evaluation.

Source: Diabetes 5. 12. 2023

News Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis

How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of axSpA were recently published in the journal Therapeutic Advances in Musculoskeletal Disease as part of the extended clinical trial ESTHER.

Source: Arthritis 19. 4. 2022

News Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma –⁠ Case Study

The incidence of NDM-producing Klebsiella pneumoniae is increasing worldwide. NDM beta-lactamase is a significant cause of multidrug resistance in enterobacteria to various antibiotics, including carbapenems. Currently, the most suitable approach for the treatment of intestinal infections caused by NDM-producing K. pneumoniae is considered to be the combination of ceftazidime/avibactam with aztreonam. The following case study also illustrates its use in more complicated cases.

Source: Anti-Infectives 3. 3. 2023

News Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective

The I-WISh survey assessed the impact of immune thrombocytopenia (ITP) and its treatment on patients' lives. Patients identified fatigue as the most frequent, severe, and persistent symptom associated with ITP, unlike doctors who did not attribute such significance to this symptom. Recently published survey results also showed that patients need support from multiple sources, including doctors, family, friends, and patient groups.

Source: Immune Thrombocytopenia 22. 10. 2021

News Use of Medical Cannabis in Patients with Fibromyalgia to Relieve Pain and Depression

Medical cannabis is prescribed to patients with chronic pain resistant to conventional treatments. The efficacy of tetrahydrocannabinol (THC) therapy in patients with fibromyalgia syndrome (FMS) was recently evaluated in a German study.

Source: Medical Cannabis 22. 4. 2024

News Angiodysplasia as a Serious Problem in Patients with von Willebrand Disease −⁠ Case Study

Bleeding into the gastrointestinal tract can become a very significant cause of morbidity and mortality in patients with von Willebrand disease (vWD). It has been described that gastrointestinal (GI) bleeding associated with angiodysplasia is more common in individuals with vWD compared to other causes. Evidence suggests that von Willebrand factor (vWF) is associated with the regulation of angiogenesis, and its deficiency increases the risk of angiodysplasia. It is also known that this type of bleeding is difficult to treat because it is associated with recurrences. The following case study also very well illustrates and summarizes this issue.

Source: Von Willebrand Disease 19. 5. 2023

News Maintaining Therapeutic Doses of Levothyroxine Throughout Shelf Life

Levothyroxine is the drug of choice for patients with hypothyroidism. However, it is also one of the substances with a narrow therapeutic range, which increases the risk of overdose or underdose, especially in risk groups. An innovative formulation of levothyroxine guarantees the maintenance of the drug content within the range of 95–105% throughout the shelf life of the product.

Source: Thyroid Disorders 23. 2. 2022

News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics –⁠ Results of a Large Meta-Analysis

Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.

Source: Modern Treatment of Schizophrenia 24. 6. 2021

News Recommendations for the diagnosis of ITP in adults and children according to ASH guidelines

The American Society of Hematology (ASH) guidelines from 2019 highlighted several important aspects in the diagnosis and treatment of ITP that have remained unchanged from the 2011 guidelines.

Source: Immune Thrombocytopenia 22. 4. 2020

News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis −⁠ True North Study Results

Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.

Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News Prediction of DM2 and CVD Development Risk Based on Lipidomic Risk Determination

The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.

Source: Modern Treatment of Diabetes 20. 5. 2022

Články časopisu Involvement of the gastrointestinal tract in amyloidosis: when to think about it and how to diagnose

Author of the article: Ryšavá R. Source: Gastroenterologie a hepatologie | 2/2019 23. 4. 2019